Viridian Therapeutics Inc

VRDN · NASDAQ

Medical Laboratories · US

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.

Market Data

Price $13.48 +0.18 (+1.35%)

Market Cap$1.36B

P/E Ratio—

EPS$—

52W High$34.29

52W Low$11.76

Beta0.84

Data from Finnhub · Updated May 1, 2026